PRESS RELEASE - April 11, 2003

Molecular Engines Laboratories (MEL) announces the publication of a comprehensive study on TSAP6, one of its main therapeutic target genes involved in tumor reversion. :


Paris, France, April 11, 2003

Molecular Engines Laboratories (MEL) announced today the publication of a comprehensive study on TSAP6, one of its main target genes involved in tumor reversion. The article ď The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinaseĒ which was published in the Proceedings of the National Academy of Sciences of the USA March 2003 edition, emphasizes once again the importance of MELís recent discoveries of new potential therapeutic targets against cancer.

TSAP6, which represents one of the companyís 3 most important therapeutic targets, and on which a significant part of the companyís molecular pharmacological program is focused, is a gene which was isolated and discovered by MELís scientific team as being involved in the process of tumor reversion of 2 leukemia and 3 breast cancer cell lines.

This new article which demonstrates through in vitro and in vivo studies that TSAP6 interacts with the Myt1 protein kinase and the Nix protein, 2 molecules known respectively for their role in cell cycle regulation and in apoptosis (programmed cell death), suggests that TSAP6 could play an important role in 2 processes which delay considerably cell growth and which induce programmed cell death.

These new data illustrate the functional role that TSAP6 plays in the cell, and more specifically during the process where a cancerous cell turns into a revertant cell with a suppressed malignant phenotype.

According to Drs. Adam TELERMAN et Robert AMSON, ďthe first concrete results brought to light by Brent Passerís team at Molecular Engines Laboratories on the functional role of TSAP6, a gene which assumes a key role in tumor suppression and of which very little was known just about 2 years ago, gives us a new perspective in a molecular context on tumor reversion, and enables us to move forward significantly with the development of innovative drugs against cancerĒ.

Tumor reversion, an innovative approach to cancer therapy conceived and developed by MELís founders and chief scientists, Drs. Adam TELERMAN and Robert AMSON, is a natural phenomenon observed in the early 1990 in which selected few cells succeed in losing spontaneously their cancerous state and revert to a suppressed malignant phenotype.

Molecular Engines Laboratories (MEL) is a private biotechnology company whose purpose is to develop novel therapeutics for cancer. MELís strategy, as conceived by Drs. Adam Telerman and Robert Amson, is to characterize most of the genes associated with tumor reversion and to understand their mechanism of action in order to induce the reversion of malignant cells to suppressed-malignant cells. For more than twenty years, numerous academic institutions and a plethora of pharmaceutical companies have been working intensively in trying to understand how normal cells become malignant. The team at MEL is taking a novel approach toward cancer research by focusing instead on how malignant cells revert to suppressed-malignant cells.


For more information, please contact: info@molecular-engines.com or consult MELís website: www.molecular-engines.com